Skip to content

Inositols and FSH in IVF

Use of Inositols Within IVF Protocols to Reduce Gonadotropin Administration

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04576546
Enrollment
300
Registered
2020-10-06
Start date
2020-11-02
Completion date
2024-02-27
Last updated
2025-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amount of FSH Units During Ovarian Stimulation Protocols

Brief summary

Ovarian hyperstimulation syndrome (OHSS), although quite uncommon, represents the most serious complication of ovulation induction during in-vitro fertilization (IVF) protocols. The syndrome is triggered by exaggerated ovarian response to gonadotropins, which eventually leads to pathological manifestations that range from mild symptoms, such as abdominal discomfort, to life-threatening complications in the most severe cases. Prevention is paramount during fertilization programs and requires assessment of risk factors and close monitoring of risk markers. Clinicians quite generally consider unusually elevated estrogen levels as both indicator for OHSS and one possible etiological factor. In this scenario, myo-inositol (MYO) treatment proved to reduce the amount of FSH units and the duration of the stimulation protocol, decreasing the risk of OHSS onset. On the other hand, inconclusive evidence is available about the effect of D-chiro-inositol (DCI) supplementation within assisted reproductive treatments. The aim of the proposed pilot study is to assess the effect of DCI supplementation on the doses of FSH used in IVF-ET protocols, also with respect to MYO treatment.

Interventions

DIETARY_SUPPLEMENTD-chiro-inositol

Supplementation of D-chiro-inositol (1000 mg/die), starting at least 4 weeks before rFSH administration

DIETARY_SUPPLEMENTMyo-inositol

Supplementation of myo-inositol (4 g/die), starting at least 4 weeks before rFSH administration

Sponsors

Lo.Li.Pharma s.r.l
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Women undergoing IVF-ET procedure * HOMA-IR index \< 2.0 * AMH in the range 1.0 - 2.0 ng/ml

Exclusion criteria

* History of cancelled IVF cycles * BMI \< 20 kg/m2 or ≥ 30 kg/m2 * Diagnosis of PCOS * Thyroid diseases * Presence of co-morbidities

Design outcomes

Primary

MeasureTime frameDescription
FSH units/retrieved oocyte1 day (single time-point at ovulation)number of IU of recombinant FSH administered, normalized on the number of oocytes retrieved during the pick-up

Secondary

MeasureTime frameDescription
Total FSH (IU)1 day (single time-point at ovulation)total number of FSH IU used in the stimulation protocol
Duration of the stimulation1 day (single time-point at ovulation)Number of days of the stimulation protocol till pick-up
number of viable oocytes1 day (single time-point at oocyte pick-up)number of retrieved oocytes eligible for fortilization
oocyte quality1 day (single time-point at oocyte pick-up)classification of oocyte quality before fertilization
embryo quality1 day (single time-point at embryo transfer)evaluation of the quality of embryos after fertilization, before transfer

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026